This is an account of almost 60 years' experience in the clinical delineation of genetic disorders, mapping genes on chromosomes, and cataloging human disease-related genes and genetic disorders. The origins of medical genetics as a clinical specialty, of the Human Genome Project, of genomics (including the term), and of HUGO are recounted.
, "the Amish madonna photograph," Heritable Disorders of Connective Tissue (45) , and Cardiovascular Sound in Health and Disease (46) . The chair came from Dr. J.E. Moore's office and was used for many years by Dr. McKusick (usually in white coat) in conducting patient conferences in the Moore Clinic.
BACKGROUND
My identical twin brother Vincent and I grew up on a dairy farm in Maine in a family that valued scholastic achievement. Our elementary schooling (it was called grade school) was in a one-room schoolhouse where the same teacher taught us seven of eight years. Following that we went off to high school in the neighboring village where we pursued a classic "college prep" course with four years of Latin, three years of French, much English literature and composition, and much history and math (algebra, geometry, and trigonometry, but no calculus), with no biology, no chemistry, and no physics.
My formal exposure to science and to genetics came late, at Tufts University, where I was a premed student for three academic years (2 1/2 calendar years), from September 1940 to January 1943. My twin and I split up when we went to college, he to Bates and I to Tufts, partly to avoid competing with each other for scholarship support but also because our career goals had diverged. Vincent had been long set for the law; my goals were altered by an experience that Vincent did not share. At the age of 15 I developed an abscess of the left axilla and a superficial spreading ulcer of the right elbow that would not heal. After many attempts to culture the causative organism(s) I ended up in the Massachusetts General Hospital where I spent 10 weeks in the summer of 1937-incredible in this age of brief hospitalizations. There a microaerophilic streptococcus was cultured that had escaped detection previously in Maine because of its fastidious cultural requirements. I got sulfanilamide ("Prontosil"), which had become available the year before. The lesions of axilla and elbow, which had been present for more than eight months, healed and stayed healed. In the process I saw much of medicine and decided that it was the field for me.
At Tufts, the biology, chemistry, and physics of the premed curriculum were fascinating to me, and I suspect I did better than many of my classmates who had been exposed to these subjects in high school and were perhaps blasé as a result. In my last semester at Tufts I took an elective course in genetics with Professor Paul A. Warren, an inspiring teacher, who made the topic of classic Mendelism exciting.
After the Pearl Harbor attacks on December 7, 1941, while I was in my second year at Tufts, the United States entered the war. To preserve my deferment as a premed student, I did a semester at Tufts in the summer of 1942, and finished up my third academic year by January 1943. In the fall of 1942 I learned that Johns Hopkins Medical School was accepting applications from undergraduate students who had not yet received a college degree, for an entering class in March 1943. For Johns Hopkins this was a shift, forced by the wartime exigencies, away from the requirement of a bachelor's degree that had existed at the school since its opening in 1893.
I was strongly attracted to Johns Hopkins because of a cover story in Time magazine in January 1939. It focused on the Hopkins professor of the history of medicine, Henry Sigerist, and his views on socialized medicine. At the same time it recounted the saga of the founding of Johns Hopkins and of its Institute of the History of Medicine. The only medical school application I submitted was for Johns Hopkins and I was accepted to matriculate in March 1943. Part of my "reverse snobbery" is that I am a college dropout. I do not have a bachelor's degree. I have only one earned degree, the MD from Johns Hopkins (1946) , but a goodly collection of honorary doctorates from universities in the United States and abroad, including Tufts.
After completing four academic years of medical school in three calendar years, my class graduated from Johns Hopkins Medical School in March 1946. I then embarked on an internship in internal medicine at the Johns Hopkins Hospital, April 1, 1946 to July 1, 1947 . I had fully expected that after medical school and a certain amount of postdoctoral training I would go back to Maine to enter the general practice of medicine. That was not to be, because of my ambitions for the internship on the prestigious Osler Medical Service with its tradition of training for academic medicine, and because of career-changing developments during my years of hospital training.
The most important influence directing me into medical genetics was a teenager named Harold Parker. He became my patient in June 1947 near the end of my Osler internship and was my introduction to the polyps-and-spots syndrome. In the next two years, four other patients with this combination came my way, three of whom were members of one family, indicating autosomal dominant inheritance. Hearing that Harold Jeghers in Boston also had 5 cases, I joined forces with him to write up these 10 cases for publication in two successive issues of the New England Journal of Medicine in late December 1949 (33) . This syndrome of jejunal and other intestinal polyps and melanin spots of the lips, buccal mucosa, and digits was subsequently named the Peutz-Jeghers syndrome, first in a paper from the Mayo Clinic in 1954 (7) . Peutz (97) had described the combination in a large Dutch family in 1921. Peutz's was not the first report, however; Jonathan Hutchinson first described the pigmentary changes in identical twins in 1896 (32) , and in 1919 F. Parkes Weber (116) reported that one of the twins had died of intestinal obstruction.
I was tutored in the genetic interpretation of the polyps-and-spots syndrome by Professor Bentley Glass, then at the Homewood Campus of Johns Hopkins University. He dissuaded me from genetic linkage as the basis of the association of polyps and spots and indicated that pleiotropism of a single mutant gene was much more likely, even though at the time we did not know what the mechanism of the association might be. Indeed, the precise connection between the two features remains unclear to this day, even though the mutant gene and specific mutation(s) have been identified.
Meanwhile, I was becoming a cardiologist. First, as a junior assistant resident on the Osler Medical Service, I read electrocardiograms in the Johns Hopkins Heart Station under the tutelage of Elliott V. Newman. Then, from 1948 to 1950, I worked in a cardiovascular unit at the U.S. Marine Hospital in Baltimore under Luther L. Terry, who subsequently achieved fame as the surgeon general of the United States Public Health Service who pointed the accusative finger at cigarettes. While there I was involved in doing cardiac catheterizations and studied the movement in the heart borders by a new method called electrokymography, in the course of which I became intimately familiar with the mechanics of cardiac function. Based on work done during that period, publications came out on chronic constrictive pericarditis (41, 42) , on successful reversion of ventricular fibrillation occurring as a complication of right heart catheterization (109), on the electrocardiographic effects of lithium chloride (then used as a salt substitute) (43) , and on other topics. The reversion of "v.fib" (109) may have been in part attributable to the use of Xylocaine (Astra), which was subsequently known as lidocaine. This agent was in trial as a local anesthetic in our cardiac catheterization laboratory. The case may have been the first instance of its use for treatment of an arrhythmia.
On July 1, 1950, I returned to Johns Hopkins and the Osler Medical Service, first as a senior assistant resident in 1950-1951 and then as the chief resident ("the Resident Physician") from 1951 to 1952. Thereafter, I stayed on the junior faculty, engaging in the combination of research, teaching, and patient care that I continue to the present.
In my first years on the Johns Hopkins University faculty, I pursued two research projects in parallel. One was the study of heart sounds and murmurs by the method of sound spectrography, which had been developed at the Bell Telephone Laboratory for analyzing speech sound ("visible speech") and which I adapted to the heart sound field, renaming it spectral phonocardiography (87, 88) . (The frequency spectrum of the heart sounds was demonstrated by the recordings.) The ultimate output from those studies was a monograph entitled Cardiovascular Sound in Health and Disease (1958) (46) . It was a comprehensive treatise on heart sounds and murmurs and on clinical auscultation, illustrated with spectral phonocardiograms. Preparing the first chapter, on the history of the field, gave me much pleasure. I have insisted that the best way to "get on top" of a field is to know how it got where it is now from where it was at the beginning. In each of the fields in which I have worked I have explored its history. Related to the heart sound field, for example, I wrote a short biography of Osborne Reynolds (89) , who devised the Reynolds number, which is relevant to the generation of turbulence in fluid flow and therefore of heart murmurs. Encountering Marfan syndrome in my clinical work in cardiology, and having been schooled in the principle of pleiotropism, it was not difficult to be impressed with the probability that the various features of that disorder-in the skeletal system, in the eye, in the aorta-could be due to a mutationdetermined defect in one element of connective tissue wherever it occurred in the body. I collected all the Marfan patients I could and studied them extensively, often retrospectively on the basis of hospital records, and studied the families firsthand insofar as possible. The Johns Hopkins Hospital was a superb site for such studies because of strong departments of ophthalmology, pediatric and adult cardiology, orthopedics, and other specialties that patients consult in connection with the various syndromal features of Marfan syndrome. Because of pleiotropism, such syndromes are often like the elephant being examined by multiple blind men. Conspicuous features in one organ system may bring the patient to the attention of one specialist to the exclusion of others.
I am mainly an autodidact in genetics. As a junior faculty person at Hopkins in the 1950s, I had access to faculty knowledgeable in genetics, particularly Bentley Glass, and association with others who like me were would-be geneticists, including Barton Childs and Abraham Lilienfeld. The four of us with others referred to ourselves as the GaltonGarrod Society. The first edition of Curt Stern's textbook Principles of Human Genetics (110) was influential in my education in genetics. Stern incorporated much information from classic genetics when dealing with phenomena for which evidence in man was limited.
MEDICAL GENETICS AS A DISTINCT CLINICAL DISCIPLINE
Medical genetics was institutionalized at Johns Hopkins on July 1, 1957. My boss, A. McGehee Harvey (69, 70) , chair of the Hopkins Department of Medicine, asked me to take over the direction of a multifaceted chronic disease clinic that had been developed by J. Earle Moore in about 1952. The arrangement I made with Dr. Harvey was that I would develop a Division of Medical Genetics within the Department of Medicine based in this clinic, which was renamed in honor of Dr. Moore. I argued that genetic disease is the ultimate in chronic disease. The objective of the new division was to serve in relation to hereditary disorders the same role that the established subspecialty divisions such as cardiology, gastroenterology, and endocrinology performed in relation to particular systems: teaching, research, and exemplary patient care (58, 67) .
I became known as a cardiologist because of my writings in the field in the 1950s, before I became known as a geneticist. Some thought I was committing professional suicide in leaving cardiology to focus on rare and "unimportant" genetic disorders. They asked why I switched from cardiology to genetics. Actually it was a matter of phasing down cardiology and ramping up genetics after 1957. The genetics of heart disease was a focus of our Moore Clinic program at the beginning, and our National Institutes of Health (NIH) support for research and training came from the National Heart Institute until the National Institute of General Medical Sciences was founded in the early 1960s. I continued involvement in the Heart Sound Laboratory until 1962. In 1961, I did a major study of Buerger disease in Korea in comparison with cases in the United States (79a). This re-established the condition as a distinct entity as opposed to being merely precocious atherosclerosis.
The newly renamed Moore Clinic was fertile soil for planting a medical genetics unit. It had evolved out of a world-class venereal disease clinic that had developed longterm follow-up mechanisms for studying the late manifestations of syphilis, such as the neurologic and cardiovascular, and the efficacy of pre-penicillin therapies such as bismuth, mercury, and arsenicals. Dr. Moore's clinic had close links to the Johns Hopkins School of Hygiene and Public Health (now the Bloomberg School of Public Health), including the statistics and epidemiology departments and the Department of Public Health Administration, which was involved in the Master of Public Health program for public health officers, who rotated through the clinic. It had good funding in connection with its new role in the area of chronic disease, including training grant funds, which at that time could be used for noncitizens.
Paradoxically, an advantage of the Moore Clinic for developing a medical genetics unit with a triple function in research, teaching, and patient care was its cramped quarters. On the second floor of the Carnegie Dispensary Building of the Johns Hopkins Hospital, facilities for patient visits, offices for staff and fellows, and cytogenetics and biochemical laboratories were crowded into a limited space that was made to do and fostered collaborations. responsibility particularly in the area of statistical genetics. Samuel H. ("Ned ") Boyer IV had come to me in 1956 as a fellow in cardiology. I proselytized him also to genetics (or he became infected by the contagious "genetics bug") and he went off to the Galton Laboratory in London for an exciting year (1957) (1958) with Lionel Penrose, Harry Harris, C.A.B. Smith, and others. His associations with Harris were especially significant and started him off on the study of biochemical polymorphism including G6PD and the hemoglobins that absorbed his attention for the next 30 years.
Education in the Moore Clinic
Other fellows were attracted to the Moore Clinic both from the United States and from abroad. Early postdoctoral fellows from Britain included David A. Price Evans, who as a postdoc did the classic study of the pharmacogenetics of isoniazid metabolism (17) [at that time the concept and the term pharmacogenetics had scarcely been invented, by Arno Motulsky (93) (13) .
In the early stages of the Moore Clinic program's development, a distinguished human geneticist spent one month in residence each year. The first of these was Curt Stern, PhD, who lived in the hospital ("under the Dome") and gave a total of 12 lectures, on Monday, Wednesday, and Friday in each week of January 1959. These lectures, held in Hurd Hall, the main auditorium of the hospital, were well attended. Several department chairmen attended most lectures. Using six blackboards tightly covered with handwritten notes as his only visual aid, Stern conveyed very well the excitement of the field. The second lecturer-in-residence was Harry Harris from London, adding a biochemical genetics slant to Stern's classic genetics. C.A.B. Smith, also from London, followed with mathematical and statistical genetics, including linkage analysis, which was by then a research emphasis of the new Division of Medical Genetics.
The Bar Harbor Course
An important part of the educational program of the Moore Clinic in its early years (and of the genetics program at Johns Hopkins to this day) was the annual two-week course at Bar Harbor, Maine, organized jointly by Johns Hopkins University and The Jackson Laboratory ( JAX). The annual session in July 2006 was the 47th, the course having been inaugurated in 1960 (22, 24, 56, 84) .
The title in its first seven annual sessions and in the even-numbered years, 1968 to 1978, inclusive, was Short Course in Medical Genetics. On odd-numbered alternate years beginning in 1967, the course focused on the mouse and was entitled Short Course in Experimental Mammalian Genetics. According to that plan, it should have been a "mouse course" in 1979, but by that time developments in somatic cell and molecular genetics had advanced to the point that the same methods were being used in the study of mouse and man, and the human had become amenable to experimental genetics to an extent not previously possible. Lecturers on a particular topic would often move back and forth between mouse and man (or other species) in an almost seamless way. The mouse-human somatic cell hybrid system was a metaphor for what had happened in the field. In 1979, the course was in its twentieth annual session and that year was the fiftieth anniversary of the JAXmore reasons to have a combined celebratory course. The title of the course in 1979 was changed to Short Course in Medical and Experimental Mammalian Genetics, and such has been the title ever since.
In the early decades of the Bar Harbor Course the faculty was approximately one third each from Hopkins, the JAX, and other institutions. In recent times, the faculty, which for a decade or more has numbered about 40, are one fourth from Hopkins, one fourth from the JAX, and one half from other institutions. More than 90 different individuals from Johns Hopkins, more than 120 from the JAX, and more than 290 from other institutions have taught in the course.
The students numbered 45 the first year; the number passed the 100 mark in the 1970s, and has been 120 per year for some time. In all, with the completion of the 2006 session, more than 4800 students have passed through the course. They represent a wide geographic distribution. The students, always a highly heterogeneous group, were of higher average age in the first decade because established clinical specialists, medical and biological educators, and even medical deans sought out the new information for aid in their clinical work, research, teaching, and curriculum planning.
Patient Care in the Moore Clinic
From the beginnings of the Moore Clinic in 1957, patients in all age groups, from womb to tomb, were cared for. The family was considered the unit of clinical practice as much as the individual patient. From the first, the Moore Clinic cared for many of my previously identified patients and families with heritable disorders of connective tissue. The development of a chromosome laboratory by Malcolm A. Ferguson-Smith in 1959 brought referrals. Early on, it may have been unclear in the mind of the public and perhaps many physicians how unlikely it was to find a visible chromosomal abnormality in disorders that were "running in families." Thus, physicians referred many patients to the Moore Clinic for chromosome studies, and many other patients were self-referred (58) .
Research in the Moore Clinic
Many research topics were pursued by members of the clinic staff. Each postdoctoral fellow had an "arbeit," many of which were inspired by patients seen in the clinic. The overarching emphasis of the research was twofold: genetic nosology (53, 54, 60) and gene mapping. For the pursuit of both of these areas, the Division of Medical Genetics was organized into five sections, each headed by a faculty member who had started out as a postdoctoral fellow. The biochemical genetics section was represented by Samuel H. Boyer IV; the cytogenetics section by Ferguson-Smith, and later Digamber Borgaonkar and others; the immunogenetics section by Wilma Bias; the mathematical and statistical genetics section by E. A. Murphy; and the clinical genetics section by myself. It is evident that these represented the areas of expertise necessary for studying inherited diseases and the areas of expertise necessary for characterizing marker traits for linkage studies, for analyzing family linkage data, and, of course, for defining phenotypes.
Genetic Nosology
Defining the multiple distinct forms of the mucopolysaccharidoses in the 1960s and early 1970s is a good example of genetic nosology in the Moore Clinic (83) . Close collaboration with Elizabeth Neufeld of the NIH, who was responsible for the cellular and biochemical differentiations, was notably useful (82) . The mucopolysaccharidoses provided nice examples of locus heterogeneity (e.g., the Sanfillippo syndromes) and allelic heterogeneity or allelic series (e.g., Hurler syndrome and Scheie syndrome) (82) .
Also in the 1960s, skeletal dysplasias became an area of both clinical and research nosologic interest because of their relationship to the heritable disorders of connective tissue, because of studies of dwarfism in the Amish (78, 79), which we initiated in 1963, and because of collaboration with Little People of America, Inc., which began in 1965 when I first attended the annual national convention of this fraternal organization of persons of short stature. Skeletal dysplasias became a major interest of many who were my fellows in that period including David Rimoin, Judith G. Hall, and Charles Scott, who like me became honorary life members of Little People of America.
The studies of the Old Order Amish demonstrated how observations in genetically isolated populations could contribute to the nosology of genetic disease (81) . Our expectation that "new" recessive disorders would be found in this inbred population was richly fulfilled (80) . The first phenotype we studied in detail in the Amish was dwarfism (78, 79, 81) , which was said to be unusually frequent. It was clear that this was not likely to be achondroplasia, which is dominant. Indeed, two forms of recessive dwarfism were found in the Amish of Lancaster County, Pennsylvania, where our studies started. One, the Ellisvan Creveld (EvC) syndrome, or six-fingered dwarfism, had been described in 1940 through the collaboration of a Scottish and a Dutch professor of pediatrics (15) . When we reported on the Amish EvC in 1964 (78), we had a total of 50 cases, living and dead. Because about 50 cases had previously been reported, by one fell swoop we doubled the world's reported cases of the disorder. The existence of a large number of Amish cases almost certainly due to the same mutation permitted a useful analysis of the range of the phenotype.
EvC syndrome in the Amish became a favorite with writers of biology textbooks as an example of founder effect. The "Amish Madonna," an Amish mother with her affected daughter demonstrating the polydactyly of this disorder, appeared in several textbooks after her debut in my Human Genetics (first edition, 1964) (50) .
The second form of recessive dwarfism that we found in the Amish was a previously unknown entity that we designated cartilagehair hypoplasia (CHH) because of the striking changes in cartilage and hair (79) . It has since become known also as metaphyseal chondrodysplasia, McKusick type. Whereas EvC was limited to the Lancaster County Amish deme, CHH was also frequent in Amish in other parts of North America, e.g., Ohio, Indiana, and Ontario.
In the initial study of CHH (79), 77 affected persons in 53 Amish sibships were identified. This cohort represented an intellectually exciting opportunity to describe from scratch a previously unrecognized disorder, including its various and variable features, including immunologic deficiency (105), chronic neutropenia (36), anemia, megacolon, lymphoma in unusual sites, herpes and other viral infections, and so on.
We and others described a large number of other "new" disorders among the Amish, which were cataloged in Medical Genetics Studies of the Amish (59), published in 1978, and in a special issue of the American Journal of Medical Genetics in 2003 (21) . The new disorders identified in the first decade of our Amish studies included the McKusick-Kaufman (77), Byler (9), Troyer (11), and Mast (10) syndromes, the last three named for affected Amish families. The causative mutations in all four of these disorders have now been characterized by the positional cloning approach (8, 96, 108, 111) .
A noteworthy finding of the Amish studies was the demonstration that the Amish in Lancaster County, Pennsylvania, in Holmes County, Ohio, and in Elkhart and Lagrange Counties, Indiana, represent partially separate demes. The separateness, resulting from different immigration histories, was indicated by differences in the frequency of family names, in blood group frequencies, and in specific genetic disorders (59) . It was as though the Amish immigrants were streaked like bacteria east-west across the waist of America, with colonies springing up first in eastern Pennsylvania and then successively in Ohio and in Indiana. In effect, a bioassay of the genomes of the founder immigrants was provided by the findings in their descendants.
Occurrence of CHH in all Amish demes suggested a high frequency of the mutant allele in the parent population. The Finns, who have no known geneologic connection with the Amish, were also found to have a relatively high frequency of CHH (37, 38) . Remarkably, the same mutation in the RMRP gene (OMIM 157660.0001) turned out to be responsible for CHH in both the Finns and the Amish (104) , suggesting that the mutation is ancient or, alternatively, recurrent. In either case, the demographic histories of the Finns and the Amish, which have some parallels, must have favored a high mutant allele frequency through founder effect and random genetic drift.
In 1963, during a visit to Hopkins, Charles Dent told me of Nina Carson's work (8a,b) describing a Marfan look-alike disorder. Subluxation of the lenses and Marfan-like skeletal changes were associated with excretion of homocystine in the urine and disastrous thrombotic accidents. Carson had detected the disorder in a urine chromotography survey in an institution for the mentally retarded in Northern Ireland. I then recalled a family I saw in 1960 in which three siblings appeared to have Marfan syndrome with dislocated lenses and "typical" skeletal features. One of the siblings died at age 18 of thrombosis of carotid arteries and a second of coronary occlusion at age 21. During Dent's visit, we confirmed that the surviving sibling had homocystine in the urine. Thereafter, Neil Schimke and I undertook a mail follow-up study of all cases of nontraumatic ectopic lentis in the files of the Wilmer Institute at Johns Hopkins and many other eye clinics. Urine was mailed to Baltimore for assay. With this approach and others, 20 families were assembled for study (105a) . Ascertained not on the basis of mental retardation but on the basis of ectopia lentis, the series showed that mental retardation is not a consistent feature of homocystinaria (one patient achieved a PhD). Homocystinuria differed from Marfan syndrome in recessive inheritance and by thrombotic (not aortic) complications as the prime cardiovascular problem.
Other notable nosologic output from the Moore Clinic included The Genetics of Hand Malformations (113a), Samia Temtamy's PhD thesis; isolated growth hormone deficiency as an autosomal recessive trait by Rimoin et al. (104a) ; microcephaly-chorioretinopathy syndrome (OMIM 251270) (86a); and cranioectodermal dysplasia (OMIM 218330) (35a).
Genetic nosology was the topic of oneweek-long conferences, entitled "Clinical Delineation of Birth Defects," held at the Johns Hopkins Hospital for five consecutive years, from 1968 to 1972. Genetic disorders in all areas of medicine were reviewed, with presentation of papers, morning and afternoon, and with a noon case conference introducing a large number of patients illustrating particular disorders that fell into the area of focus in that day's lectures. The conferences and the publications emanating from them gave my colleagues in all departments of the Johns Hopkins Hospital a chance to present their experiences with rare or not so rare genetic disorders.
The importance of clear delineation of distinct genetic clinical entities was emphasized by the conferences, such definition being necessary for proper prognostication and www.annualreviews.org • A 60-Year Tale of Spots, Maps, and Genesmanagement in individual cases as well as for genetic counseling. Such delineation was also necessary to achieve "pure culture" groups of cases for determining the basic defect and pathogenic mechanisms. Three main principles of clinical genetics that underlie genetic nosology-pleiotropism, variability, and genetic heterogeneity-were discussed with numerous examples. My lecture on the first day of the first conference in May 1968, entitled "On lumpers and splitters: the nosology of genetic disease" (54) , addressed the issue of genetic heterogeneity and others. The proceedings of the conferences, both the papers presented and full reports of the noon conference patients, were published as a series of Birth Defects "Blue Books" by the March of Dimes, which funded the conferences. See, for example, the 396-page monograph on skeletal dysplasias (4) that came out of the two days of the first (1968) conference devoted to that topic.
A certain excitement, and as Robert Gorlin put it, charisma, accompanied the conferences that came from the intellectual challenges of differential diagnosis and consideration of the nature of basic defects and developmental mechanisms. James German commented that if he had known that clinical genetics could be so exciting he might not have left his clinical position at Cornell-New York Hospital to go to the New York Blood Center a few years earlier. These conferences gave academic respectability to the disciplines of syndromology and dysmorphology. No longer could these fields be considered mere postage stamp collecting.
At all the conferences, a number of "living eponyms" were present, e.g., Dent, George Fraser, François, Gardner, Klinefelter, Lamy, Laron, Menkes, and Noonan. Many, including Gorlin and Opitz, became eponymically established on the basis of these conferences. In the five conferences I count a total of 40 such "living eponyms," some of whom did not yet know they were such.
By necessity, the naming of genetic disorders, including the appropriateness of eponyms, came up for discussion at the conferences on the Clinical Delineation of Birth Defects. Incidentally, the possessive form of eponyms was consistently eschewed in the conference publications. Use of the nonpossessive form was already established in my own writings. Although I wrote "Marfan's syndrome" in March 1955 (44) , it was always "Marfan syndrome" beginning with the first edition of Heritable Disorders of Connective Tissue (1956) (45) . In all my writings since then, such as the annotated annual reviews of medical genetics (74, 76) 
Gene Mapping
I am not certain why, in the late 1950s, I became enthralled with mapping genes on human chromosomes. Certainly I was impressed with the gene mapping that had been done in other species such as Drosophila and the mouse. The maps gave a concreteness to the genes. In the 1950s I was also impressed by the reports of human autosomal linkages (of unknown chromosomal location) by Jan Mohr in 1951 (91), by Renwick & Lawler in 1955 (100a) , and by Newton Morton in 1956 (92) , and I had some vague sense of the probable significance of such linkages to clinical medicine, as had been pointed out by J.B.S. Haldane (25) and by others. I had begun thinking along the lines of linkage studies and had applied for grant support for such studies before Curt Stern, during his onemonth stay in the Moore Clinic in 1959, encouraged me, pointing out that the arrangement of genes on our chromosomes is an important feature of our anatomy. The anatomic metaphor is something I have since used extensively (62, 63, 66, 71, 73) . Sometimes I have mixed the anatomic and cartographic metaphors, as in the title of a 1981 lecture: "The human genome through the eyes of Mercator and Vesalius" (63) . I entitled a long four-part review of gene mapping in clinical medicine "The morbid anatomy of the human genome" (66) , and another review in 2001 "The anatomy of the human genome, a neoVesalian basis for medicine in the 21st century" (71) .
One of my first ventures into genetic linkage was done with Ian Porter (98, 99) , who was a postdoctoral fellow in the Moore Clinic from 1960 to 1962. This was a study of the genetic interval between the locus for G6PD deficiency and that for colorblindness (CB).
[The only X chromosome linkage interval that had previously been estimated was that between CB and hemophilia, by J.B.S. Haldane and C.A.B. Smith in 1947 (26) .] Both G6PD and CB are X-linked polymorphic traits. The study was begun with a survey of CB in African American boys in a Baltimore elementary school. The frequency of CB is less in that ethnic group than in Caucasians, perhaps 3.5% compared with 7% in European Americans. The colorblind boys were then tested for G6PD deficiency to identify a group of families in which both traits were segregating. An attempt was made to test all males in a given sibship and to test the maternal grandfather of the affected males. The grandfather provided information on the linkage phase of the two traits in his double-carrier daughters: If the mother of the boys in the test generation had the two traits in coupling, her father was either doubly affected or completely unaffected. If the mother had the two traits in repulsion, her father was either colorblind or G6PD deficient but not both and not neither. The Porter family studies indicated a close relationship of the G6PD and CB loci, with about 5% recombination between them. This close positioning was confirmed by other mapping and molecular studies of the generich telomeric region of the long arm of the X chromosome.
Linkage work in the Moore Clinic in the 1960s was greatly abetted by collaboration with James H. Renwick (98, 99) and the analysis of possible linkage of XG and CB by Renwick & Schulze (102) . Renwick was involved in several other Moore Clinic linkage studies (2), including assignment of the Duffy blood group locus to chromosome 1 in 1968 (13) . A notable contribution by Renwick in the same period was the introduction of the useful term synteny (and syntenic), meaning "on the same chromosome" as opposed to linkage (and linked). It was in a superb review of human gene mapping (99a), in which he introduced and defined the term synteny, which he derived from the Greek syn = together and taenia = ribbon. He took to task two groups (104b,c) who the previous year had reported that lactic acid dehydrogenase (LDHB; OMIM 150100) and peptidase-B (PEPB; OMIM 169900) are "linked" on the basis of somatic cell hybrid studies. Renwick pointed out that the somatic cell hybrid method can prove synteny but not linkage (in the strict genetic sense). In fact, it turned out that LDHB and PEPB are on different arms of chromosome 12.
Mann et al.'s (39) discovery of the Xlinked blood group antigen Xg(a) in 1962 led to a flurry of investigations in families with X-linked disorders. These excluded linkage for almost all loci tested (102), a finding not now surprising because of the known location of the XG locus near the end of the short arm of the X chromosome (14a), which is one of the larger ones of the human complement.
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Even though syntenic to XG, they were not genetically linked to XG. Several of our autosomal linkage studies in the 1960s came to naught largely because of the pitifully small collection of marker traits then available. Disappointingly negative autosomal linkage studies included those of Marfan syndrome (107) and of the large kindred with symphalangism (112) that the noted neurosurgeon Harvey Cushing described and named in 1915 (12) . [The Cushing article with large fold-out pedigree was in the first volume of Genetics, which also carried Calvin Bridges's classic paper (6) on nondisjunction as proof of the chromosome theory of heredity.] Both Marfan syndrome (OMIM 154700) and symphalangism (OMIM 185800) were later mapped when DNA markers became available, and the mapping information was used to determine the basic defect in the genes encoding fibrillin-1 (FBN1; OMIM 134797) and noggin (NOG; OMIM 602991), respectively.
Positive results of linkage studies from the Moore Clinic in the 1960s included mapping of the interval between nail-patella syndrome and the adenylate kinase locus (106); Renwick & Lawler (100a) had already linked nail-patella syndrome to the ABO locus.
[Ferguson-Smith et al. (18, 19) later assigned the NP/ABO/AK1 gene cluster to 9q34.1.] Harper et al.'s (28) demonstration that secretor status of the fetus can be determined by studying amniotic fluid meant that one could do prenatal diagnosis of myotonic dystrophy, whose close linkage to secretor (and lutheran) we confirmed (29) . The most exciting result in the 1960s was the first assignment of a specific locus to a specific autosome, Duffy blood group to chromosome 1, by Donahue et al. in 1968 (13) . Donahue was a PhD candidate in human genetics and although his thesis topic was in another area he studied his own karyotype and found a heteromorphism of the chromosome 1 pair. One chromosome of the pair was longer than the other and in the preparations of that just-prebanding era looked as though it had an uncoiled segment subjacent to the centromere. Donahue had both the wit and the gumption to do a linkage study: the wit to recognize the heteromorphism as a probably normal variant transmitted as an autosomal dominant, and the gumption to collect blood for chromosome and marker studies from members of a far-flung family and perform the chromosome and marker testing.The lod score calculable for the linkage of the blood group with the heteromorphic chromosome 1 that Roger Donahue found in himself and some other members of his family was low. However, the assignment was confirmed by other workers studying the same heteromorphism (118) and other markers in the centromeric region of 1q.
From the paltry collection of positive results from much mapping work it is clear why in 1967 I welcomed with enthusiasm Weiss & Green's (117) development of the method of interspecies somatic cell hybridization as it was an alternative method for assigning genes to specific chromosomes or regions of chromosomes. It substituted the variation between the two species in the hybrid for the variation between the paternal and maternal alleles in family studies. It was not necessary, for example, to have a polymorphism of a given enzyme such as thymidine kinase to map it to chromosome 17, in one of the first applications of the method to chromosome mapping (90) . And it is clear why I welcomed equally or even more enthusiastically the use of DNA markers [at the beginning, restriction fragment length polymorphisms (RFLPs)] for linkage study, as spelled out especially clearly by David Botstein, Ray White, Mark Skolnick, and Ron Davis in a seminal paper that introduced the term RFLP in 1980 (5).
The annual or biennial Human Gene Mapping (HGM) workshops initiated in 1973 were Frank Ruddle's idea. He was a pioneer in the use of interspecies somatic cell hybridization for assigning genes to specific chromosomes in mouse and man. As noted, I was active in the linkage approach to gene mapping in the human. A regular member of the faculty of the Bar Harbor Short Course in Medical Genetics, Ruddle solicited my collaboration in the organization of the HGM workshops. He trusted that I would be able to arrange funding from the March of Dimes, which funded the Bar Harbor Course and the Clinical Delineation of Birth Defects conferences, and on whose medical advisory committee I had served since 1959. The idea of the HGM workshops was enthusiastically received by the March of Dimes and was implemented by Dr. Daniel Bergsma, vice president for professional education. The first HGM workshop was held in New Haven under the leadership of Ruddle in 1973. The dates and organizers of the subsequent conferences are indicated in Figure 1 .
The HGM workshops served an important function in the collation of gene map information both published and unpublished over a period of two decades. Persons attending the workshops submitted abstracts of unpublished works. Committees comprising persons who worked on the mapping of particular chromosomes vetted the published and unpublished information accumulated since the previous conference. Reports of the chromosome committees were published by the March of Dimes as part of its Birth Defects series and appeared as a supplement to the journal Cytogenetics and Cell Genetics. The workshops had a committee on comparative gene mapping, as well as a committee on nomenclature that attempted to standardize names of genes and gene symbols and establish conventions for indicating the cytogenetic band location of genes.
The HGM workshops were a forerunner for the Human Genome Organisation (HUGO); indeed, in its conferences and standing committees (that on nomenclature, for example), HUGO assumed most of their functions. Abandonment of the workshops, as they had been known for 18 years, occurred after the London workshop of 1991. The change met with the displeasure of many of the HGM workshop faithful who had come to value greatly the charm, comradery, and effectiveness of the previous workshops. The annual or biennial five-day-long endeavor represented hard work by the participants, who took great pride in the finished product.
By June 1976, at least one gene locus had been assigned to all 22 autosomes and the X and Y, testis determining factor (TDF) being the first gene assigned to the Y chromosome. The same milestone, at least one gene known on each chromosome, was achieved at about the same time in the mouse. In 1977, Ruddle and I published a review in Science entitled "The status of the human gene map" (85) . In 1986, in the immediate pregenomics era, I gave another status report (65) . By then, about 600 genes had been assigned to specific chromosomes and in most cases to specific regions of chromosomes.
THE ROLE OF THE POLIO VACCINE IN THE DEVELOPMENT OF MEDICAL GENETICS
The efficacy and safety of the Salk polio vaccine was announced by The National Foundation for Infantile Paralysis on April 12, 1955 . Known also as the March of Dimes (MOD), the organization considered that its goal had now been achieved and looked around for new worlds to conquer. It settled on birth defects and arthritis as appropriate fields in which to work. (Arthritis was abandoned after a few years.)
The polio vaccine was important to the development of medical genetics because the MOD could now turn its considerable expertise in fundraising and public information to medical genetics. The polio foundation had already fostered the early development of molecular genetics by supporting Max Delbrüch, for example; James D. Watson was a National Foundation fellow when he went to work in a Copenhagen polio virus laboratory, later switching to the Cavendish Laboratory at Cambridge.
I claim some credit for establishing with the National Foundation the principle that birth defects fall into the domain of medical genetics. When I heard of the MOD's shift in focus, I sent a copy of the first (1956) edition of Heritable Disorders of Connective Tissue (45) to Thomas M. Rivers, Rockefeller Institute researcher, who was vice president of research at the MOD. Rivers was a loyal Hopkins medical alumnus, with training in pediatrics at the Johns Hopkins Hospital. I think it was through him that I was invited to join the MOD medical advisory committee in 1959.
The shift of the powerful MOD organization to the field of birth defects (read "medical genetics") had its effect on education, clinical care, and research. In education, the MOD was the sole funder of the Bar Harbor Short Course for its first 25 sessions, from 1960 to 1984, and to this day provides some support. In clinical care, the effect of the MOD was evidenced in the annual conferences on the Clinical Delineation of Birth Defects held at Johns Hopkins from 1968 to 1972 and elsewhere thereafter, and was supported exclusively by the MOD. In research, the role of the MOD was evidenced by the HGM workshops from 1973 to 1991, which for much of that period were supported by the MOD.
THE HUMAN GENOME PROJECT
From early on, several of us who were enthusiasts and aficionados of gene mapping championed the usefulness of mapping all the genes in the human. For example, in August 1969 at the International Conference on Birth Defects sponsored by the MOD in The Hague (55) , I proposed that mapping all the genes would be a useful approach to understanding the basic derangements in birth defects. In part, the proposal reflected the exuberant mind-set that followed the first moon landing by Apollo 11, carrying Neil Armstrong and Buzz Aldrin, on July 10, 1969.
In 1980 (61) I suggested that it should be possible to map all the genes by the end of the last ventade (20 years, parallel to decade) of the twentieth century, i.e., by the year 2000. It was not clear by what methods mapping could be achieved and it was not clear precisely how the use of this complete information would help the understanding of birth defects and their diagnosis and management. Of course, it is molecular genetics that has permitted the complete mapping of the genes, and it is positional cloning of genes mutant in "mystery diseases" that has represented a major, but not the only, way in which gene mapping has permitted elucidation of the molecular defects of birth defects.
As Walter Gilbert pointed out to me during the deliberations of the National Research Council/National Academy of Sciences (NRC/NAS) committee on mapping and sequencing the human genome (94), complete sequencing would be necessary just to find all the genes.
The Human Genome Project as an endeavor to completely sequence the human genome was first formally proposed in 1985 by Robert Sinsheimer, by Charles DeLisi, by Renato Dulbecco (14) (who championed complete sequencing as an approach to understanding cancer), and by others.
In May 1986, the Cold Spring Harbor symposium was entitled "The Human Genome." By that time the Human Genome Project was a hotly debated topic, with parties both favoring and opposing it. A rump session, chaired by Paul Berg and Walter Gilbert, was held to discuss the proposed project for complete sequencing. James Watson raised the question of why the Department of Energy should be undertaking the project, the implication being that the NIH would be more appropriate. One reason given by one of the moderators was that if multiple agencies were involved there would be more total funding for the project. From the first, however, a justification of the Department of Energy's involvement lay in the responsibility that agency had for studying the biologic effects of radiation.
At that Cold Spring Harbor symposium in 1986, I gave a paper on the status of the human gene map (65) . I think it was an eye-opener to molecular biologists. It was also at that Cold Spring Harbor symposium, or soon thereafter, that Brian Crawford, of Academic Press, suggested that I edit a new journal on mapping and sequencing. I was reluctant to undertake this, but was reassured when Ruddle agreed to join me as coeditor-in-chief. We proposed to name the journal Genome, a term attributed by the Oxford English Dictionary to the German botanist Hans Winkler (1920) and formed by combining the words GENe and chromosOME. However, we found that we had been scooped by the Canadian Journal of Genetics and Cytology (1959-1986) , which had chosen to rename that journal Genome. Although one cannot copyright the title of a book or a journal, we shied away from Genome. In July 1986, over beer after an evening session of the editorial board of the new journal, Thomas H. Roderick of the JAX proposed Genomics as the title.
During the next year, plans for Genomics were laid and the first issue was published in September 1987. The inaugural editorial in the first issue was entitled "Genomics: a new discipline, a new name, a new journal" (86) . Nine years later, a stock-taking editorial was entitled "Genomics: an established discipline, a commonly used name, a mature journal" (34) .
During the period of 1986-1988, the question of whether complete sequencing of the human DNA could be done and should be done continued to be actively discussed. A vocal few opposed it as being extravagantly expensive and not representing true science, or at least having questionable usefulness. The idea that it was not science was born particularly out of the hypothesis-driven research mindset. The Human Genome Project, as has since been often pointed out, represents discovery and hypothesis-generating research.
A major factor in the federal government's funding of the Human Genome Project was the report prepared by the NRC/NAS committee on mapping and sequencing the human genome, which was commissioned in late 1986 and reported out in February 1988 (94) . The committee was chaired by Bruce Alberts and made up of the following, in addition to me: Botstein, Brenner, Cantor, Doolittle, Hood, Nathans, Olson, Orkin, Rosenberg, Ruddle, Tilghman, Tooze, and Watson. Because of his involvement with commercial development of sequencing apparatus, Michael Hunkapiller resigned early from the committee to avoid conflict of interest.
The report of the committee concluded that the project should be done; that it could be completed in 15 years at an annual budget of $200 million; that "map first, sequence later" was the appropriate approach because the mapping of DNA markers and cloned fragments would provide a useful scaffolding for sequencing, and particularly because sequence technology at that time was not very efficient; that the sequence of other genomes should be determined in parallel with that of the human; and so on.
Clearly, the report of the NAS/NRC committee (94) influenced Congress's funding of the Human Genome Project, which was to be done jointly by the Department of Energy and the NIH. The NIH project was officially initiated October 1, 1990, with James Watson as the first director of the National Center for
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Human Genome Research (NCHGR). On January 1, 1993, Francis S. Collins took over as director of the center, which was given institute status as the National Human Genome Research Institute.
The Human Genome Project was being discussed and planned by scientists in other countries as well, and in 1988 HUGO was founded as a coordinating agency for the global effort. Sydney Brenner, James Watson, Lee Hood, and others proposed HUGO at the 1988 Cold Spring Harbor symposium, and at a rump session I was invited to serve as organizing president. I was selected, I suppose, because of my role in the international HGM workshops, all of which I had attended, and on the basis of which I had maintained an ongoing record of the status of the human gene map.
The first task was to assemble a founding council to write a mission statement and bylaws for HUGO. At Watson's suggestion, the first meeting of the council in September 1988 was held in Montreux, Switzerland, to give HUGO an international cachet, and HUGO was incorporated in Geneva, hence the spelling organisation in its name. HUGO was subsequently incorporated also in Delaware to facilitate handling of funds in the United States. The Montreux founding meeting was attended by 31 scientists, including 5 Nobelists (Dausset, Dulbecco, Gilbert, Jacob, and Watson), from 19 countries (66a).
Funding of HUGO in its beginning and for several years thereafter was provided by the Howard Hughes Medical Institute (HHMI) through the agency of its vice president, George F. Cahill, Jr. The HHMI also supported the development of OMIM (see below) beginning in 1985 and for six or seven years thereafter. It had supported in part the last several biennial HGM workshops. Thus, in relation to these three developments, HHMI played the same role as had the March of Dimes in relation to the Bar Harbor Course, the Conferences on the Clinical Delineation of Birth Defects, and most of the HGM workshops.
The objectives and functions of HUGO related to intellectual property rights, ethical issues, research materials, information sharing, and nomenclature standardization. HUGO was never conceived as a funding agency; it has always been a coordinating agency for the various genome projects funded by national governments.
After my term as founder president, I served as cochair of the HUGO ethics committee and was a member of the ethics committee for the NCHGR. At the outset, Watson wisely decided that funding should be provided in the budget of the NCHGR for the study of what he termed ELSI, for ethical, legal, and societal implications, or issues (presumably he and his staff devised this felicitous acronym).
Following the "map first, sequence later" recommendation of the NRC/NAS committee, the effort at the beginning of the NIH program was to construct genetic maps (marker maps) and physical maps (contig maps) of the genome, such as yeast artificial chromosome (YAC) maps-a top-down approach. In contrast, Craig Venter and Hamilton Smith used a bottom-up approach to achieve for the first time the complete sequence of the genome of a free-living organism, H. influenzae, reported in 1995 (20) . The single chromosome of the bacterium was fragmented into many pieces. In a shotgun approach, fragments were cloned as bacterial artificial chromosomes (BACs) and the DNA was sequenced several times over to increase the likelihood that all the BACs were sequenced at least once. Then the complete sequence was assembled using overlaps of ends of BAC clones. In the next few years, this approach was used for sequencing many other organisms including Drosophila and man.
I first learned of Venter's work in genomics through his 1991 report on the sequencing and mapping of complementary DNAs (cDNAs), which he called expressed sequence tags (ESTs) (1). I had been impressed by the potential usefulness of going directly to the functional part of the genome as a shortcut in the effort to "map all the genes." Complete sequencing of the H. influenzae genome was done in The Institute for Genomic Research (TIGR) in Rockville, Maryland, which Venter founded in 1992. In 1998, when he founded the company Celera to undertake the complete sequencing of the human genome, Venter asked me to join the Celera scientific advisory board. I found participation as a board member stimulating because of the association with Hamilton ("Ham") Smith and Venter and with the other members of the board, as well as the excitement of the undertaking. The Venter enterprise was severely criticized by many who saw a threat to the open and free (i.e., at no cost) access to the sequence data. See, for example, the discourse by Sulston & Ferry (113) . It was obvious that complete sequencing of the large human genome was a major undertaking. One approach was an industrial one funded in the way industry is customarily funded, i.e., sale of the product. The business plan of Celera called for licensing of access to the data and the computer programs for their analysis. The second approach was to parcel out the effort to multiple laboratories in multiple countries with funding from governmental and foundation sources. Open and free access was important, perhaps essential, to the approach by international consortium.
I did not sense that a commercial approach was unethical, and in retrospect I conclude that the "completion" of the Human Genome Project was accelerated by the competition that the private effort introduced. Venter assembled an array of computer equipment, second only to that at NASA, to analyze the data produced by large banks of sequencers. The name Celera (as in acCELERAte) and the company's motto "Discovery cannot wait" indicate the Venter style of urgency that accompanied the effort. An announcement of the Venter map and of the map created by the international consortium led by Francis Collins was made at the White House on June 26, 2000. The two maps were published separately in Science (114) and Nature (35) , respectively, in February 2001.
MENDELIAN INHERITANCE IN MAN (MIM) AND ITS ONLINE VERSION (OMIM)
OMIM (95) is the internet version of Mendelian Inheritance in Man (MIM) (52), a catalog of human genes and genetic disorders that I began in the early 1960s as a catalog of mendelizing phenotypes. The subtitle of the first 10 of the 12 book editions published to date was "Catalogs of Autosomal Dominant, Autosomal Recessive and X-linked Phenotypes." The first phenotype catalog, that for X-linked traits (48, 51) , was assembled to answer the question of the genetic constitution of the X chromosome. The second, the recessive catalog, was prepared as a resource in connection with study of recessive disorders in the Amish (81) . The autosomal dominant catalog was then undertaken for the sake of completeness. Mendelian Inheritance in Man was first published in book form in 1966 (52) . For the eleventh (1994) and twelfth (1998) editions (68a), the subtitle was changed to "Catalogs of Human Genes and Genetic Disorders," a reflection of progress in the field from phenotypic characterization of hereditary disorders to DNA definition.
Mendelian Inheritance in Man has been maintained on the computer since 1964. With the first print edition in 1966, it was a pioneer in computer-based publication. In the 1980s, MIM was prepared for online presentation, with a search engine that enhanced its usefulness. Online access, as OMIM, was provided generally beginning in 1987, first from the Welch Medical Library at Johns Hopkins and since December 1995 from the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (27) .
The conception of Mendelian Inheritance in Man was rooted in the annual annotated reviews of medical genetics my colleagues and I prepared in six successive years, 1958-1963, inclusive (74, 76 (48) . This reviewed the exciting information then developing on the role of the sex chromosomes in sex determination and on the mechanism of X chromosome dosage compensation as reflected in the Lyon hypothesis. The monograph, which was also published in somewhat modified book form in 1964 (51), sought to answer the question of what genetic information is carried by the X chromosome by listing all of the X-linked traits. For each trait the preferred designation, a description of the trait, and detailed information on its genetics, with bibliographic references to support the statements, were given-the format subsequently used for entries in Mendelian Inheritance in Man.
The last of the six annual reviews of medical genetics for the Journal of Chronic Diseases was that for the year 1963 (75) . By that time the usefulness of genetic studies in the Amish had come to my attention through the unpublished manuscript of John Hostetler's Amish Society, and through a story in a drug company "throw away" about a physician in Lancaster County, Dr. David Krusen, who had many Amish patients, including some with dwarfism. We expected that studies in the Amish would reveal new recessive disorders (80) , and in preparation for the studies we assembled a catalog of known recessive disorders. Rather than continuing annual reviews, we were attracted to the idea of creating a comprehensive catalog of Mendelian phenotypes, such as we had done for X-linked and autosomal recessive phenotypes, to which additions could be made as new phenotypes were described and information on the "old" phenotypes became available. Thus, a catalog of autosomal dominant traits was added. In early 1964 the catalogs were "put on the computer" (the mainframe at the Homewood campus of Johns Hopkins University) to avoid introducing errors in the file with updating, and to simplify indexing and publication; the word processor was not yet available.
The first three editions of MIM (1966, 1968, and 1971) were in all uppercase font because of limitations of the printer available for preparing the camera copy for photo-offset publication. Beginning with the fourth edition (1975), automatic typesetting has provided conventional type styles.
I did the lion's share of the authoring and editing of MIM for all print editions, ably aided by editorial assistants, particularly Carol Bocchini, who has worked on MIM full time since 1979 and has served as writer/editorial director of OMIM since 1998. In the ninth (1990) and the tenth (1992) editions, the title page indicated "with the assistance of Clair A. Francomano, MD, and Stylianos E. Antonarakis, MD." To these was added Peter L. Pearson, PhD, in the eleventh edition (1994); and Antonarakis, Francomano, Orest Hurko, MD, Alan F. Scott, PhD, David Valle, MD, and others in the twelfth edition (1998). Since 1998, a distributed authorship/editorship has been achieved, with the involvement of an estimated eight full-time equivalents working as writers and editors at Hopkins and elsewhere. Since 1986, Joanna Strayer Amberger, now OMIM project manager, has had charge of bibliographic review, assignments to writers and editors, and upkeep of the gene map and other tables. Ada
Hamosh (27) has been the scientific director of the OMIM project for several years.
From 1973 to 1985, I was chair of the Department of Medicine of the Johns Hopkins University School of Medicine and physicianin-chief of the Johns Hopkins Hospital. I reveled in the teaching of medical students and residents. From the distinguished careers in genetics of several of those students and residents, it appears that through teaching in a framework of classic Oslerian medicine I may have helped bring genetics into mainstream medicine.
I did not find the administrative responsibilities of the University's largest academic department excessively onerous, nor those of the clinical department of the Johns Hopkins Hospital-despite the fact that during that 12-year period there was a major rebuilding of the hospital, a reorganization of the Osler residency program into four firms, and a decentralization of hospital administration into six clinical functional units. Planning for the structural rebuilding required my input as department chairman. The rebuilding resulted in a major change from a departmentby-department pavilion-type layout to a horizontal layering of the inpatient units of each department through several buildings, as well as a 180
• switch of the front door from N.
Broadway to N. Wolfe St. in 1979.
On the clinical side of the Department of Medicine, in 1975 I reorganized the Osler residency, and the inpatient hospital units on which the residents worked, into four firms (57), each with its chief (assistant chief of service) and main in-hospital unit. Later, Robert M. Heyssel, then president of the Johns Hopkins Hospital, reorganized the hospital's administration into six "Functional Units," essentially six separate hospitals, of which the Department of Medicine was one, each with a functional unit director, the chair of the clinical department, who was responsible for its administration, budget, and nursing personnel (30) .
Despite these busy and important hospital responsibilities, and those related to directing a large research-oriented university department, I enjoyed the 12 years as chair. As chairman from 1973 to 1985, I could still continue the academic triathlon of teaching, patient care, and research I have now engaged in for 60 years. I mention all this here because the continuous updating of MIM, one of my main contacts with genetics research while I was chairman, had to be done in evenings and weekends. It was a pleasant respite from hospital and university business. Keeping up MIM, building the human gene map through the HGM workshops and the literature, and organizing and directing the annual two-week course at Bar Harbor assured that I did not fall behind in the science and practice of medical genetics. On the urging of Dean Richard S. Ross, I stepped down from the chairmanship in 1985, two years earlier than was mandated by the rule of retirement at age 65. This, as it turned out, was a fortunate move because I was free to participate in the planning of the Human Genome Project (1986) (1987) (1988) (1989) (1990) and in the launching of OMIM (1987), the journal Genomics (1987), and HUGO (1988), as well as to produce a book version of Mendelian Inheritance in Man at two-year intervals from 1986 (seventh edition) to 1994 (eleventh edition).
Two areas of particular focus in the assembly of MIM (and OMIM) have been (a) the nature of the basic defects of hereditary disorders, and (b) the chromosomal map location of the mutant genes that underlie them. For 40 years an attempt has been made to be comprehensive in recording information in these two domains. The two domains are more closely related than I had expected; chromosome mapping of mutant phenotypes became a main approach ("positional cloning") to defining basic defects of "mystery diseases" in the last quarter century.
In the third book edition of MIM (1971), a tabulation of known autosomal linkages and chromosomal assignments was published in the "front material"; it occupied only a single page. In subsequent print editions, chromosome-by-chromosome tables of mapped genes have been presented, and the same table, kept up on an ongoing basis, has been accessible in the NCBI internet version, OMIM. The last print edition (1998) devoted 116 pages to the tabular synopsis of the human gene map and I estimate that the January 2006 map in OMIM would require at least 256 printed pages in the same layout.
The nature of the basic defects in hereditary disorders was tabulated beginning in the fourth edition (1975), with a listing of enzymopathies and one of structural protein variants (polymorphism) as part of the "front material." The known amino acid substitutions in hemoglobin variants were cataloged from the beginning; for example, the first edition (1966) listed the amino acid changes in a dozen or more variants of the β-globin chain. The second edition (1968) had a comprehensive tabulation of known amino acid changes in variant hemoglobins, which was appended to the entry for the particular globin type. This was the forerunner of the practice of listing descriptions of individual allelic variants after the entry for the gene. The allelic variants are given a unique entry number of 10 digits formed by adding .0001 and so on to the six-digit entry number for the gene. Allelic variants numbered in this way were first listed in the seventh print edition (1986). Thus, the common mutation responsible for cystic fibrosis, deletion of amino acid residue phenylalamine-508, carries the entry number 602421.0001. [602421 is the entry number for the CFTR gene, which is mutant in cystic fibrosis; 219700 is the number of the entry describing the phenotype(s) and genetics of cystic fibrosis.]
With the accelerating identification of mutant genes and specific DNA changes in genetic disorders, the number of entries with listed allelic variants has increased rapidly (1a). As of May 1, 2006, OMIM had identified 1871 genes in which at least one diseaserelated mutation had been described. Because many genes are the site of different (allelic) mutations causing multiple distinct phenotypes, the total number of phenotypes for which the molecular basis had been identified as residing in one of these 1871 genes was 3112.
All genes that have been identified as the site of disease-related mutations have been mapped to specific chromosomal sites. Therefore, the "Disorder" field in the tabular presentation of the gene map, which can be accessed online directly from the OMIM entry for a particular gene, lists the distinct disorders that are known to be related to mutation in that gene.
The Economic considerations make a multivolume (the 1998, or twelfth edition, is in three volumes) print edition less practical; internet access to OMIM, which is updated essentially daily, makes the periodic print edition less necessary. Nonetheless, the historian in me grieves the loss of the historical record that can be retrieved more easily from the successive print editions.
For the first eight editions of MIM , the individual entries were assembled, organized, and updated in a diachronic ("through time") or historical mode, rather than the descriptive or synchronic ("one point in time") mode characteristic of encyclopedias and textbooks. The historical approach is that used by the Oxford English Dictionary, which has other parallels to MIM. Beginning with the ninth edition (1990), many long entries in OMIM were reorganized into topical sections, within each of which the diachronic sequence was usually retained. For a long time, at least 10 years, most new entries have been organized in topical sections at the time of creation.
The heavy use of OMIM is reflected by the large number of users who visit the internet site daily. The wide use and depth of information in OMIM is reflected by the following statistics on May 18, 2006: approximately 15,300,000 references to OMIM are listed by Google. (Google has approximately 16,300,000 references to the Encyclopedia Britannica and 33,200,000 to the Oxford English Dictionary.) Every phenotype and every gene discussed in OMIM appears to be indexed in Google, as well as many symptoms, signs, laboratory tests, and so on.
In a letter to the editor of the New England Journal of Medicine, the correspondent (23) described a clinical case conference in which the diagnosis was not made by a distinguished visiting professor, but by a resident. When asked how she made it, the resident said she consulted Google using the signs, symptoms, and test findings. A Boston pediatricianbioinformatician tells me that when he makes teaching rounds he tells his students and residents to consult Google and OMIM for help with diagnostically puzzling cases.
The clinical usefulness of OMIM in clinical diagnosis is indicated by the above anecdote. Its usefulness in research is evident in the fields of gene mapping and identification of basic molecular defects. OMIM is also useful in teaching. In 1993, I published "Medical Genetics: A Self-Instruction Guide and Workbook Based on (Online) Mendelian Inheritance in Man" (68) . This consisted of a set of questions the answers to which could be found in OMIM, with the help of the search engine available at that time.
CONCLUDING COMMENT
This personal account spans almost 60 years from the polyps-and-spots syndrome to the present. It seems appropriate that it should finish with a discussion of OMIM, which chronicles the phenomenal advances that represent the present scientific and clinical base for the discipline of medical genetics and also much of our understanding of the genetics and genomics of our species.
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